Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial

Ozguroglu, M.Kilickap, S.Sezer, A.Gumus, M.Bondarenko, I.Gogishvili, M.Nechaeva, M.Schenker, M.Cicin, I.Ho, G. F.Kulyaba, Y.Dvorkin, M.Zyuhal, K.Scheusan, R. I.Li, S.Pouliot, J-F.Seebach, F.Lowy, I.Gullo, G.Rietschel, P.2023-01-022023-01-0220220923-7534https://reader.elsevier.com/reader/sd/pii/S0923753422039345?token=71A2014D03917840BAA6B9F5FF6D27514DC3A1A11C5ACA71B082418092AA82EE053976F23B46425060D9A4E2069A7D6B&originRegion=eu-west-1&originCreation=20230102073637http://hdl.handle.net/11727/8488enginfo:eu-repo/semantics/openAccessThree Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 TrialConference Object33714211421000866211602466